Halozyme Therapeutics, Inc. (HALO): Total Liabilities
$2.48B
As of 2025-12-31
$2.43B
As of 2026-06-30
+14.0%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.48B | +45.7% | 2026-02-17, Balance as of period end |
| 2024-12-31 | $1.70B | +3.0% | 2026-02-17, Balance as of period end |
| 2023-12-31 | $1.65B | -1.3% | 2025-02-18, Balance as of period end |
| 2022-12-31 | $1.67B | n/a | 2024-02-20, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.48B | +45.7% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.30B | -40.3% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $3.69B | +13.8% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $633.31M | -34.5% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $683.10M | -2.9% |
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.38B | +22.1% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.92M | +5.2% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $218.73M | +43.5% |
Compare HALO, NVAX, MRNA, BCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗